About Us
About Us
Leadership
Our Culture

Leadership

    Founding Team
    • +
      Mingyao Liu

      Founder、Chairman、Chief Scientist

      Mingyao Liu

      Founder、Chairman、Chief Scientist

      PhD

      Distinguished Experts, Chair Professor

      Professor LIU earned his Ph.D. in Cell Biology from University of Maryland in College Park, and then did his postdoctoral trainings in Johns Hopkins University School of Medicine, and in California Institute of Technology Division of Biology, USA.  He was a tenured full professor in the Institute of Biosciences and Technology, Texas A&M University, and the graduate faculty member in the University of Texas Houston Medical School and UT MD Anderson Cancer Center.  After returned to China, Prof. LIU has served as the Dean of Life Sciences for 8 years and has been the Director of Institute of Biomedical Sciences, East China Normal University in Shanghai.

      Prof. LIU's research interests focus on cell signaling, cell therapy, gene editing and gene therapy in different diseases. He has published more than 400 research papers in top journals, such as Nature, Science, Nature Biotechnology, Nature Medicine, etc .  He has won the first prize of National Science and Technology Progress Award, the first prize of Shanghai Science and Technology Progress Award, and the Shanghai Magnolia Memorial Award.

    • +
      Zaixi Xi

      Founder,Vice Chairman

      Zaixi Xi

      Founder,Vice Chairman

      EMBA of China Europe International Business School and Tsinghua University

      Shanghai Minhang Leading Talent

      Serial Entrepreneur

      XI is a serial entrepreneur with a strong sense of corporate mission and entrepreneurial spirit, emphasizing strategic height and execution. According to his rich experience in operation, management and  investment, involving various fields such as biomedicine, great health, and real estate, he currently serves as a core member of the board of directors and the company's decision-making and management committee to drive the development of BRL Medicine.

    Core Management Team
    • +
      Biao Zheng

      Senior Partner、Chief Executive Officer(CEO)

      Biao Zheng

      Senior Partner、Chief Executive Officer(CEO)

      PhD

      Dr. Biao Zheng graduated from the medical department of the Medical College of Zhejiang University with a bachelor's degree in clinical medicine. He received his MS and PhD in Immunology from Fudan University School of Medicine and King's College, University of London, respectively. Dr.  Zheng has taught at the University of Maryland School of Medicine and Duke University Medical Center. Subsequently, he served as a tenured professor in the Department of Pathology and Immunology at Baylor College of Medicine. Dr. Zheng has published a number of papers in the world top journals such as Nature and Science.

      Dr. Zheng joined GlaxoSmithKline R&D Center in 2010 as the head of Immunological Discovery Sciences. In 2015, he joined Johnson & Johnson as global vice president in Global Immunology Therapeutic Area, Janssen Pharmaceuticals, and Johnson & Johnson Innovation Center, Asia Pacific. Before joining BRL Medicine Inc., he joined IASO Biotherapeutics as the chief scientific officer 2020.

      Dr. Zheng has more than 30 years of experience in the pharmaceutical industry, especially in the field of immunotherapy (macromolecular antibody, cell therapy, etc.). He has deep insights and experience in drug development, international medical environment, market access and commercialization.

    • +
      Frank Gao

      Senior Partner、Chief Strategy Officer

      Frank Gao

      Senior Partner、Chief Strategy Officer

      PhD

      Dr. Gao has a doctorate in pharmacokinetics and a master degree in pharmacy from China Pharmaceutical University, and a bachelor degree in pharmacy from Shandong University. Before joining BRL Medicine Inc., Dr. Gao had nearly 20 years of management and development experience in the pharmaceutical industry. He played critical roles in a range of pharmaceutical areas including regulatory agency, multinational pharmaceutical enterprise, biotechnology company and global leading CRO which enabled him owning the key of the whole chain of the pharmaceutical industry, especially in drug development strategy, regulatory strategy, quality strategy and commercialization strategy. He used to be a senior reviewer in Center for Drug Evaluation (CDE) of China National Pharmaceutical Product Administration, reviewed thousands of applications and performed dozens of on-site inspections within 8 years, covering Investigational New Drug Application (IND), New Drug Application (NDA), Abbreviated New Drug Application (ANDA) and post marketing supplement application in cross indication fields. Dr. Gao has a comprehensive and profound understanding in regulatory science and regulatory/technical guidelines from CDE, FDA, EMA and ICH. In Eli Lilly, he served as the head of regulatory CMC and medical devices, led CMC strategy, technology transfer strategy and medical device registration strategy for Lilly innovative assets, participated in Lilly new generation R&D reform, and provided technical support in R&D and commercialization for Lilly alliance projects in China. Meanwhile, he served as the rotating chairman of CMC Committee of RDPAC, led seven working groups, made outstanding contributions to support China authority to build a new drug innovation ecosystem. He served as regulatory affairs director in AscentagePharm to lead China and US R&D and registration strategies, and successfully got several oncology new drugs’IND in both China and USA. Later, he served as principle R&D and regulatory consultant in Parexel, help about 30 domestic and foreign biopharmaceutical companies on 50 projects’R&D and regulatory strategies to successfully get regulatory approval in China and USA. In spare time, Dr. Gao actively explores and practices in the area of artificial intelligence and digital technology to empower drug R&D, and designed and developed a remote intelligent clinical trial platform.

    • +
      Dali Li

      Co-founder, Vice President

      Dali Li

      Co-founder, Vice President

      PhD , Professor at East China Normal University

      Dr. Li is a pioneer in the field of innovative genome editing tool development and CRISPR-based gene therapy. He has published more than 100 research articles in high impact journals, including Nature Biotechnology, Nature Genetics and Nature Cell Biology, and developed several novel editing tools, such as hyCBE and A&C-BEmax.

    • +
      Yuxuan Wu

      Co-founder, Vice President

      Yuxuan Wu

      Co-founder, Vice President

      PhD , Post-Doctoral Harvard University, Researcher of East China Normal University

      Researcher Yuxuan Wu has published more than 10 relevant research papers in recent years in several journals including internationally renowned academic journals Nature Medicine, Cell Stem Cell, Cell Research, Nature Genetics and Nature Biotechnology. A number of works have been widely recognized and highly evaluated by domestic and international peers, majoring in combining gene editing technology (CRISPR) with hematopoietic stem cell transplantation for the treatment of thalassemia and other blood disorders. He was selected as a "Zijiang Outstanding Young Scholar" of East China Normal University in 2018.

    • +
      Bing Du

      Co-founder, Vice President

      Bing Du

      Co-founder, Vice President

      PhD , Professor of East China Normal University

      Prof. Bing Du is mainly engaged in regulation of tumor immune microenvironment and cancer immune therapy. In recent years, he has published more than 40 SCI papers in the high impact journals such as Science Advances, Cancer Research, Cancer Immunology Research, Cellular & Molecular Immunology and Mucosal Immunology. Meanwhile, he has been authorized more than 10 national invention patents in the past few years.

    • +
      Fuying Li

      Co-partner, Vice President, Regulatory Affairs Department Head

      Fuying Li

      Co-partner, Vice President, Regulatory Affairs Department Head

      Fuying Li graduated from Peking University Health Science Center in 2003 with a Master's degree in Biochemistry and Molecular Biology (dedicated in gene therapy for oncology), and a Bachelor's degree in Clinical Medicine. After graduation from university, she started her career in an innovative drug R&D center as a research scientist for 5 years, and then joined multinational pharmaceutical companies in Regulatory Affairs role, first in Pfizer China for 4 years and then Lilly China for 9 years, holding various positions in the Regulatory Department until the most recent role as Regulatory Affairs Director. Prior to joining BRL Medicine Inc., Fuying Li was responsible for Neuro-Science diseases, Auto-immune diseases and Lilly future gene therapy product registration in China, covering drug registration strategy development, regulatory submission, interaction with regulatory agencies, obtaining drug approval documents from China regulatory authority and post-marketing license maintenance for approved drugs.

    • +
      Wei Li

      Co-Partner, Vice President, VP of Medical Affairs

      Wei Li

      Co-Partner, Vice President, VP of Medical Affairs

      PhD

      As the VP of Medical Affairs of BRL Medicine, Dr. Wei Li has extensive experience in the clinical development and transformation of stem cell and immune cell therapy projects, and is fully responsible for the company's clinical development strategy and clinical operation affairs of gene and cell therapy products. He is in charge of the formulation of clinical development strategy, the establishment of clinical research protocols and related documents, development of collaborating clinical sites and clinical trial operation, to achieve the medical research results that meet drug approval requirements.

    • +
      Jiqin Zhang

      Co-Partner, Vice President, R&D

      Jiqin Zhang

      Co-Partner, Vice President, R&D

      PhD , AssociateProfessor

      Jiqin Zhang is focused on the research of gene editing and tumor immune cell therapy. In recent years, he has published more than 20 SCI papers in international journals such as Nature, Nature Communications, Cell Research, Molecular Cancer and Hypertension. As a leader, he has taken charge of two projects of National Natural Science Foundation of China and one project of Shanghai Natural Science Foundation. He also participated in several national and provincial scientific research projects. He has developed an international first non-viral genome specific targeted CAR T cell technology, established the Quikin CART® platform with BRL proprietary intellectual property, providing new strategies to break through the limitations of current CAR T cell therapy.

    • +
      Binghe Tan

      Co-Partner, Vice President of Production and CMC

      Binghe Tan

      Co-Partner, Vice President of Production and CMC

      PhD

      During his graduate studies, Dr. Binghe Tan focused on the role and mechanism of G protein-coupled receptors and their signaling in the regulation of tumor immunity, exploring the regulation of G protein-coupled receptor-mediated immune cell function and revealing the important roles and mechanisms of macrophages, T cells and other immune cells in the tumor microenvironment. In addition, he has been working on immunotherapy based on the regulation of tumor immune microenvironment. His postdoctoral work focuses on the genericization and functional enhancement of chimeric antigen receptor T cells (CAR-T) using gene editing technology, as well as the development and optimization of engineered T cell preparation processes, with the aim of achieving safety, efficacy and stability goals of universal CART (UCART) in clinical translational applications. He has been published as first author and co-author in Cancer Research, Journal of Immunology, Journal of Biological Chemistry, Science China Life Sciences, Cellular & Molecular Immunology, etc. He has applied for one international invention patent and four Chinese invention patents, one of which has been transferred. He presided over one National Natural Science Foundation of China (NSFC) youth project and participated in several NSFC surface projects as a key technicaldirector.

    • +
      Nan Xu

      Co-Partner, Chief Human Resource Officer

      Nan Xu

      Co-Partner, Chief Human Resource Officer

      MBA of Wuhan University

      CPM® International Certified Property Manager, Certified Instructor of Leadership and Human Resource ManagementNan Xu has worked in human resource management in Dowell Group, Shimao Group, China Resources Group and China Vanke. She has served as HR administrative director of commercial section, assistant HR director of the group, head of HR administration of regional companies, and senior manager of performance management of the group. Has nearly twenty years of experience in organizational development, corporate culture and talent management. Served as a volunteer for the Dima Charity Foundation during the novel coronavirus outbreak, coordinating the procurement of overseas medical supplies. Now she is responsible for the management of human resources, administration and public affairs of the company.

    • +
      Anling Huang

      Co-Partner, Director of Marketing & Intellectual Property

      Anling Huang

      Co-Partner, Director of Marketing & Intellectual Property

      Anling Huang graduated from East China Normal University with a Master's degree in Biochemistry and Molecular Biology. She won the nomination award of top 30 cutting-edge women in China's intellectual property circle in 2021 and published 3 papers in International Academic Journals. Anling is responsible for company's Intellectual Property & Marketing affairs, and has led the company to obtain honorary titles such as "Shanghai patent pilot enterprise" and "intellectual property management system certification certificate".

Back to top